MedTrace Logo

Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder

NCT01512004 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2012-01-25

No results posted yet for this study

Summary

The purpose of this Phase III study is to evaluate the efficacy and safety of Propiverine Hydrochloride Extended-Release Capsule in the treatment of overactive bladder in Chinese population with urgent micturition, frequent micturition and/or urge urinary incontinence.

Conditions

Interventions

DRUG

Propiverine Hydrochloride

drug of oral capsule

DRUG

Tolterodine Extended-release Tablet

4mg/tablet; oral; once per day

Sponsors & Collaborators

  • APOGEPHA Arzneimittel GmbH

    collaborator INDUSTRY

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Principal Investigators

  • Benjamin Li, PhD · Lee's Pharmaceutical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-01-31
Completion
2011-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01512004 on ClinicalTrials.gov